Prostate Cancer Incidence in Turkey: An Epidemiological Study

  • Zorlu, Ferruh (Department of Urology, Ministry of Health Tepecik Research and Training Hospital) ;
  • Divrik, Rauf Taner (Department of Urology, Sifa University, School of Medicine) ;
  • Eser, Sultan (Institute of Public Health, Hacettepe University, Ankara, Izmir Cancer Registry) ;
  • Yorukoglu, Kutsal (Department of Pathology, Dokuz Eylul University Faculty of Medicine)
  • Published : 2014.11.28


Background: This study aimed to determine the incidence of prostate cancer in Turkey in a population-based sample, and to determine clinical and pathological characteristics of the cases. Materials and Methods: All newly diagnosed prostate cancer patients were included in this national, multi-centered, prospective and non-interventional epidemiological registry study conducted in 12 cities representing the 12 regions of Turkey from July 2008 to June 2009. The population-based sample comprised 4,150 patients with a recent prostate cancer diagnosis. Results: Age-adjusted prostate cancer incidence rate was 35 cases per 100,000 in Turkey. At the time of diagnosis, median age was 68, median PSA level was 10.0 ng/mL. Digital rectal examination was abnormal in 36.2% of 3,218 tested cases. Most patients had urologic complaints. The main diagnostic method was transrectal ultrasound guided biopsy (87.8%). Gleason score was ${\leq}6$ in 49.1%, 7 in 27.8% and >7 in 20.6% of the cases. There was a statistically significant positive correlation between serum PSA level and Gleason score (p=0.000). The majority of patients (54.4%) had clinical stage T1c. Conclusions: This is the first population-based national data of incidence with the histopathological characteristics of prostate cancer in Turkey. Prostate cancer remains an important public health concern in Turkey with continual increase in the incidence and significant burden on healthcare resources.


  1. Albasri A, El-Siddig A, Hussainy A, et al (2014). Histopathologic characterization of prostate diseases in Madinah, Saudi Arabia. Asian Pac J Cancer Prev, 15, 4175-9.
  2. Arshad H, Ahmad Z (2013). Overview of benign and malignant prostatic disease in Pakistani patients: a clinical and histopathological perspective. Asian Pac J Cancer Prev, 14, 3005-10.
  3. Auvinen A, Forman D, Bray F, et al (2010). Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer, 46, 3040-52.
  4. Bostwick DG, Djakiew D, Burke HB, et al (2004). Human prostate cancer risk factors. Cancer, 101, 2371-90.
  5. Cal C, Zorlu F, Ozkan M, et al (2009). Incidence and epidemiological features of cancers of the genitourinary tract in Izmir between 1993-2002. Asian Pac J Cancer Prev, 10, 491-96.
  6. Cheng CW, Sim HG, (2005). Changing demography of prostate cancer in Asia. Eur J Cancer, 41, 834-45.
  7. Chirpaz E, Menegoz F, Colonna M, et al (2002). Incidence and mortality trends for prostate cancer in 5 French areas from 1982 to 1996. Int J Cancer, 97, 372-6.
  8. Coker AL, Perez A, Peltz G, et al (2006). A multilevel analysis of socioeconomic status and prostate cancer risk. Ann Epidemiol, 16, 901-7.
  9. Eser S, Yakut C, Ozdemir R, et al (2010). Cancer incidence rates in Turkey in 2006: a detailed registry based estimation. Asian Pac J Cancer Prev, 11, 1731-9.
  10. Freedland SJ, Buschemeyer WC (2007).Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol, 52, 331-43.
  11. Giovannucci E, Rimm EB, Liu Y, et al (2003). Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst, 95, 1240-44.
  12. Grivas N, Hastazeris K, Kafarakis V, et al (2012). Prostate cancer epidemiology in a rural area of Nort Western Greece, Asian Pac J Cancer Prev, 13, 999-1002.
  13. Ismail SI, Soubani M, Nimri JM, et al (2013), Cancer incidence in Jordan from 1996 to 2009-A comprehensive study, Asian Pac J Cancer Prev, 14, 3527-34.
  14. Jemal A, Naishadham D, Siegel R (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
  15. Johannesen-Henry CT, Marsa K, Johnsen NF, et al (2008). Social inequality and incidence of and survival from male genital cancer in a population-based study in Denmark, 1994-2003. Eur J Cancer, 44, 2018-29.
  16. Konety BR, Cooperberg MR, Carroll PR, et al (2011). The example of CaPSURE: lessons learned from a national disease registry. World J Urol, 29, 265-71.
  17. Majeed FA, Burgess NA (1994). Trends in death rates and registration rates for prostate cancer in England and Wales. BJU, 73, 377-81.
  18. Minana B, Gomez-Veiga F, Cozar JM, et al (2012). Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010. BJU Int, 110, 701-6.
  19. Moradpour F, Fatemi Z (2013). Estimation of the projections of the incidence rates, mortality and prevalence due to common cancer sites in Isfahan, Iran, Asian Pac J Cancer Prev, 14, 3581-3585.
  20. Neuhouser ML, Goodman PJ, Gong Z, et al (2006). Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev, 15, 1977-83.
  21. Long XJ, Lin S, Sun YN, et al (2012). Diabetes mellitus and prostate cancer risk in Asian countries: a meta-analysis, Asian Pac J Cancer Prev, 13, 4097-100.
  22. Parker AS, Cerhan JR, Putnam SD, et al (2000). Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol, 10, 361-69.
  23. Potosky AL, Levin DL, Feuer EJ (2001). Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev, 1, 181-6.
  24. Potosky AL, Miller BA, Kramer BS, et al (1995). The role of increasing detection in he rising incidence of prostate cancer. JAMA, 273, 548-52.
  25. Quaglia A, Martinez-Garcia C, Coebergh JW, et al (2003). Differences in the epidemic rise and decrease of prostate cancer among areas in Southern Europe. An analysis of differential trends in incidence and mortality in France, Italy and Spain. Eur J Cancer, 39, 4-65.
  26. Sobrino-Najul E, Ferris-I-Tortajada J, Garcia- I-Castell J, et al (2011). [Non dietetic environmental risk factors in prostate cancer]. Actas Urol Esp, 35, 289-95.
  27. Wang CY, Gunderson K, Wang R (2011). Global prostate cancer incidence and the migration, settlement, and admixture history of the Northern Europeans. Cancer Epidemiol, 35, 320-7.
  28. Weed DL, Breslow RA (1998). Review of epidemiologic studies of alcohol and prostate cancer: 1971-1996. Nutr Cancer, 30, 1-13.
  29. Xie WC, Chan MH, Mak KC, et al (2012). Trends in the incidence of 15 common cancers in Hong Kong, 1983-2008, Asian Pac J Cancer Prev, 13, 3911-6.

Cited by

  1. Frequency of Unnecessarily Biopsies among Patients with Suspicion of Prostate Cancer in Syrian Men vol.16, pp.14, 2015,
  2. Evaluation of Biochemical Recurrence-free Survival after Radical Prostatectomy by Cancer of the Prostate Risk Assessment Post-Surgical (CAPRA-S) Score vol.16, pp.6, 2015,
  3. Prostate Cancer in Iran: Trends in Incidence and Morphological and Epidemiological Characteristics vol.17, pp.2, 2016,
  4. Communication preferences of patients with prostate cancer vol.55, pp.10, 2016,
  5. Needs of Patients with Prostate Cancer for Home Care vol.5, pp.4, 2018,
  6. Epidemiology of prostate cancer in Asian countries vol.25, pp.6, 2018,